Clinical Trials

Study Title:
Multicenter, Open-Label, Phase 2 Study of Carboplatin Plus Mirvetuximab Soravtansine Followed by Mirvetuximab Soravtansine Continuation in Folate Receptor-Alpha Positive, Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Following 1 Prior Line of Platinum-Based Chemotherapy

For more information about the trial above please contact the study team: